Published in Surg Endosc on December 01, 2010
Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg (2008) 4.95
Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg (2005) 4.35
The impact of comorbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results. Ann Surg (2008) 2.33
Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol (2009) 2.10
Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treat Rev (2008) 2.00
Is totally laparoscopic gastrectomy less invasive than laparoscopy-assisted gastrectomy?: prospective, multicenter study. J Gastrointest Surg (2008) 1.77
Intracorporeal stapled anastomosis following laparoscopic segmental gastrectomy for gastric cancer: technical report and surgical outcomes. Surg Endosc (2009) 1.64
Laparoscopic gastrectomy for gastric cancer: experience with more than 600 cases. Surg Endosc (2008) 1.22
Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol (2009) 1.20
Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc (2009) 1.00
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol (2007) 2.27
Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol (2004) 1.48
New technology-based innovation changes surgical practice and research direction in solid cancers. Surg Endosc (2010) 1.39
The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev (2004) 1.18
From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices (2013) 1.16
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn (2009) 1.05
Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn (2009) 1.04
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol (2012) 1.01
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 1.01
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg (2009) 0.99
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol (2009) 0.99
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther (2006) 0.99
Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics (2010) 0.99
Impact of spleen preservation in patients with gastric cancer. Anticancer Res (2005) 0.99
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med (2010) 0.99
CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol (2009) 0.99
Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther (2009) 0.98
Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn (2009) 0.97
Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol (2008) 0.96
Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg (2009) 0.95
Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther (2005) 0.95
Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg (2009) 0.94
Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices (2010) 0.93
Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn (2010) 0.92
Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol (2009) 0.92
Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg (2008) 0.92
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol (2007) 0.91
Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol (2009) 0.90
Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn (2010) 0.90
Radiation therapy for breast cancer. N Engl J Med (2009) 0.89
Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol (2011) 0.89
Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther (2010) 0.89
Systems medicine: a real approach for future personalized oncology? Pharmacogenomics (2010) 0.89
Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol (2002) 0.88
Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices (2011) 0.88
Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics (2011) 0.88
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc (2008) 0.87
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices (2011) 0.87
From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther (2010) 0.87
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther (2009) 0.86
Laparoscopic total gastrectomy: further progress in gastric cancer. Surg Endosc (2010) 0.86
Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol (2010) 0.86
Linking contralateral breast cancer with genetics. Radiother Oncol (2008) 0.85
Isolated tumor cells in breast cancer. N Engl J Med (2009) 0.85
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2008) 0.84
Breast-cancer stromal cells with TP53 mutations. N Engl J Med (2008) 0.84
Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol (2002) 0.84
Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann Surg Oncol (2008) 0.83
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol (2002) 0.83
'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn (2011) 0.83
Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Rev Mol Diagn (2011) 0.83
Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol (2002) 0.83
Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncol (2015) 0.83
Genomics and challenges toward personalized breast cancer local control. J Clin Oncol (2008) 0.82
Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol (2002) 0.82
Gastric volvulus and wandering spleen: a rare surgical emergency. Case Rep Surg (2013) 0.82
Clinical relevance of cancer genome sequencing. World J Gastroenterol (2013) 0.82
Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Scand J Gastroenterol (2007) 0.82
More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol (2008) 0.81
Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics (2012) 0.81
Successful Nonoperative Management of Spontaneous Splenic Hematoma and Hemoperitoneum due to CMV Infection. Case Rep Gastrointest Med (2012) 0.81
New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Rev Gastroenterol Hepatol (2011) 0.81
Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn (2012) 0.81
Clinical cancer genome and precision medicine. Ann Surg Oncol (2012) 0.80
Small bowel adenocarcinoma presenting as a first manifestation of Crohn's disease: report of a case, and a literature review. Eur J Gastroenterol Hepatol (2002) 0.80
Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol (2004) 0.80
Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices (2012) 0.80
Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol (2003) 0.79
Innovation versus evidence: to trust direct-to-consumer personal genomic tests? Expert Rev Mol Diagn (2011) 0.79
Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit? Future Oncol (2014) 0.79
Emerging personalized oncology: sequencing and systems strategies. Future Oncol (2012) 0.79
Contralateral prophylactic mastectomy: mind the genetics. J Clin Oncol (2008) 0.79
PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Rev Anticancer Ther (2011) 0.79
Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. Ann Surg (2010) 0.78
Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Rev Anticancer Ther (2011) 0.78
Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Expert Rev Proteomics (2012) 0.77
Research and clinical applications of cancer genome sequencing. Curr Opin Obstet Gynecol (2013) 0.77
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol (2010) 0.77
BMI and lymph node ratio may predict clinical outcomes of gastric cancer. Future Oncol (2014) 0.77
Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. Ann Surg Oncol (2008) 0.77
Translating cancer genomes sequencing revolution into surgical oncology practice. J Surg Res (2010) 0.77
Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics (2011) 0.77
Innovative biomarker development for personalized medicine in breast cancer care. Biomark Med (2011) 0.77
Fruits and vegetables: do they protect from gastric cancer? Gastroenterology (2003) 0.77
Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Rev Gastroenterol Hepatol (2011) 0.77
Cancer heterogeneity and signaling network-based drug target. Pharmacogenomics (2013) 0.77
Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics (2012) 0.77
From traditional molecular biology to network oncology. Future Oncol (2011) 0.76
Cancer genome sequencing and potential application in oncology. Future Oncol (2010) 0.76
Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer. Future Oncol (2015) 0.76
Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management. Expert Rev Mol Diagn (2011) 0.76